



Alfresa Group

Corporate Profile

2025-2026



The Alfresa Group, serving as social infrastructure indispensable for sustaining people's health and lives through pharmaceuticals and related products, supports the supply chain as one unified group and responds to all needs concerning health.



Corporate Name and Logo



alfresa

The name “Alfresa” combines the English word “all” with the Esperanto word “fresa,” which means “fresh.”

The corporate name symbolizes our wish to be a corporation that contributes to the happiness of all people by meeting their healthcare needs and creating an active lifestyle for the coming era.

The Alfresa Group's Principles

 **Our Philosophy**  We create and deliver a fresh life for all.

 **Our Vision**  We aim to become a Healthcare Consortium that provides products and services in every health-related field.

 **Our Promises**  **Reliability Safety Sincerity**

- We always provide reliable products and services and strive to enhance customer satisfaction.
- We respect individual characteristics and personalities and strive to maintain and improve a pleasant working environment.
- We raise corporate value as a corporate group operating in the health-related industry.
- We conduct proper trade under fair and free competition.
- We strive to proactively engage with society by providing appropriate information in a timely manner.
- We contribute to local communities through our business operations.
- We strive to conserve the global environment.

Top Message

One of the Alfresa Group's principles is expressed in Our Philosophy, which is to create and deliver a fresh life for all. Another such principle is expressed in Our Vision, which is to become a Healthcare Consortium that provides products and services in every health-related field.

The business environment around the Alfresa Group is changing dramatically. The sources of volatility include the super-aged society, a shrinking workforce, the rising cost of social security, technological innovation and digitization, a pharmaceuticals supply crunch, rising logistics and labor costs, and soaring energy prices.

Amid these changes in the business environment, April 2025 saw the start of 25-27 Mid-term Management Plan Vision 2032 Stage 2 "Pioneering the Future with Our Collective Strength," which is positioned as the second stage in our efforts to achieve the goals of the Alfresa Group's Medium- to Long-Term Vision, a growth strategy running up to the year ending March 2033. The Group, which supports the supply chain of medicines, provides total supply chain services in a group-wide manner, from introduction, development, and manufacturing of medicines to its distribution, sales, post-marketing surveillance, and last-mile operations, as the pillar of its business strategy. We aim to create social values such as extension of healthy life expectancy, contribution to local healthcare to support this, and healthcare innovation.

We strive to realize a sustainable society as a group that has taken on a role in the social infrastructure of delivering medicines in a safe, secure, and sincere manner.


Ryuji Arakawa



Trends in sales and operating profit of the Alfresa Group

The Alfresa Group was established as a corporate group engaged in the wholesaling of ethical pharmaceuticals and in the manufacturing business, and has grown through management integrations and mergers. By building a nationwide distribution network, we came to hold the position of Japan's top wholesaler of ethical pharmaceuticals in 2009. Since then, we have grown into today's Alfresa Group through initiatives such as reorganizing the Self-Medication Products Wholesaling Business, strengthening the Manufacturing Business, making the Dispensing Pharmacy Business and the SPD Business wholly owned subsidiaries, expanding the network of the Diagnostic Reagent Wholesaling Business, developing the Regenerative Medicine-related Business, expanding the CRO* Business, and enhancing PMS Business functions.

Net sales / Operating profit



* An organization specializing in supporting a series of operations related to clinical trials conducted by pharmaceutical companies and research institutions

Alfresa Group's Data



* Figures as of March 2025

Business Overview

The Alfresa Group's main businesses are the Ethical Pharmaceuticals Wholesaling Business, the Self-Medication Products Wholesaling Business, the Manufacturing Business, the Dispensing Pharmacy and Related businesses, the Overseas Business, and other businesses such as the Regenerative Medicine-Related Business. Through these businesses, we aim to realize the Healthcare Consortium that provides products and services across all areas of health, and we will contribute to people's well-being.

(1) Ethical Pharmaceuticals Wholesaling Business



Focusing on ethical pharmaceuticals, we deliver a wide range of products—including diagnostic reagents, medical devices and materials, and nutritional foods— from our distribution centers— which are located across Japan and are capable of accurately handling a high throughput— to hospitals, clinics, and dispensing pharmacies. In addition, our expert sales force provides support to our customers. We are contributing to the health of community members by meeting their healthcare needs.

(2) Self-Medication Products Wholesaling Business



The Self-Medication Products Wholesaling Business focuses on over-the-counter drugs and delivers them, as well as health foods, supplements, and other products, to drugstores and pharmacies. We meet customer needs as a Total Healthcare Merchandising Wholesaler (THMW), offering a full product lineup, a reliable product supply system, and high-value-added marketing activities that help customers with questions such as how to create optimal storefronts.

(3) Manufacturing Business



From a comprehensive perspective encompassing prevention, diagnosis, and treatment, we manufacture and market high-quality active pharmaceutical ingredients (APIs), pharmaceuticals, diagnostic reagents, and medical devices that meet GMP*1 and QMS*2 requirements. We research, develop, manufacture, and market unique and distinctive products, and undertake contract manufacturing of pharmaceuticals.

*1 GMP (good manufacturing practice): Standards for manufacturing control and quality control of pharmaceuticals and quasi-drugs

*2 QMS (quality management system): Standards for manufacturing control and quality control of medical devices and external diagnostic reagents

(4) Dispensing Pharmacy and Related businesses



As community-based pharmacies, we aim to serve as “family pharmacies” that support every stage from prevention to terminal care, and are advancing initiatives such as strengthening home healthcare to enhancing functions.

(5) Overseas Business



We are expanding business through alliances with overseas companies, primarily in Asia. In China, we established the joint venture REMEJE PHARMACEUTICALS (CHINA) CO., LTD. in 2005 as a representative office for pharmaceuticals and healthcare-related products. In Vietnam, we established the joint venture Alfresa Codupha Healthcare Vietnam Co., Ltd. (Alcophya) in 2013, to conduct import and sales, mainly of medical devices and materials and diagnostic reagents.

(6) Regenerative Medicine-Related Business



We are advancing our core businesses of manufacturing and storing master cells, as well as the CMO*1 and CDMO*2 businesses. To build a comprehensive regenerative medicine total supply chain service in Japan, we will strengthen both our in-house systems and our alliances so that we can provide all necessary functions in an integrated manner.

*1 Contracted and delegated manufacturing of pharmaceuticals from pharmaceutical companies and others

*2 Services that contract from the development of pharmaceutical manufacturing processes through to the manufacturing of investigational and commercial drugs

The Alfresa Group's Medium-to long-Term Vision

Based on its Group Principles, the Alfresa Group announced in May 2023 the Alfresa Group Medium- to Long-Term Vision, a medium- to long-term target through the fiscal year ending March 2033, to create social value such as extending healthy life expectancies, contributing to community healthcare, and fostering healthcare innovation. We are pursuing business strategies for core businesses, growth businesses, and new businesses, aiming to strengthen and expand our Total Supply Chain Services (TSCS).




Alfresa Group Medium- to Long-Term Vision



Position of the Alfresa Group's Medium-term Management Plan

The 25–27 Mid-term Management Plan represents the second stage toward achieving the targets of the Medium- to Long-Term Vision, positioning these three years for priority investments and cost optimization to ensure steady profit growth, while further advancing our initiatives to date.



Group Management Policies

In the 25–27 Mid-term Management Plan, we set forth five Group management policies: “Exercising of the Group’s collective strength for the evolution and expansion of total supply chain services,” “Strategic investment in growth businesses and new businesses,” “Further strengthening of the competitiveness of core businesses,” “Rigorous cost control,” and “Implementation of sustainability management.”

Vision2032 Stage2

Pioneering the Future with Our Collective Strength

- 1 | Exercising of the Group’s collective strength for the evolution and expansion of total supply chain services
- 2 | Strategic investment in growth businesses and new businesses
- 3 | Further strengthening of the competitiveness of core businesses
- 4 | Rigorous cost control
- 5 | Implementation of sustainability management

Stage 2 towards achieving our Medium- to Long-Term Vision -
Three years of priority investments and cost optimization to achieve steady profit growth

25–27 Mid-term Management Plan ➡




TSCS

Total Supply Chain Services (TSCS) refers to establishing a seamless supply chain through the organic integrated utilization of the various functions possessed by the entire Alfresa Group and providing, as a united entity, services ranging from pharmaceutical licensing and development, manufacturing, distribution, and sales to post-marketing surveillance/last mile. In the 25–27 Mid-term Management Plan, we will demonstrate the Group’s collective strength to establish the TSCS model, aiming to secure limited-distribution products, expand the CDMO*1 business, and ensure stable supply chain operations.




Initiatives under the 25–27 Mid-term Management Plan



*1 Services that contract from the development of pharmaceutical manufacturing processes through to the manufacturing of investigational and commercial drugs
*2 Organizations that support clinical development
*3 Salespeople at pharmaceutical manufacturers

The Alfresa Group



Alfresa Group Companies

1 Ethical Pharmaceuticals Wholesaling Business

1 Alfresa Corporation
Representative: Yusuke Fukujin, President
Head office: 7, Kanda-Mitoshirocho, Chiyoda-ku, Tokyo
Business domain: Ethical Pharmaceuticals Wholesaling Business

2 Shikoku Alfresa Corporation
Representative: Yosuke Kiyoshita, President
Head office: 1255-10, Fuke Kou, Kokubunji-cho, Takamatsu, Kagawa Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

3 TS Alfresa Corporation
Representative: Takuji Takahashi, President
Head office: 1-2-19, Shoko Center, Nishi-ku, Hiroshima, Hiroshima Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

4 Meisho Co., Ltd.
Representative: Hiromitsu Kawajiri, President
Head office: Ha 1, Muryoji-machi, Kanazawa, Ishikawa Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

5 RYUYAKU CO., LTD.
Representative: Katsuya Higa, President
Head office: 5-6-5, Makiminato, Urasoe, Okinawa Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

6 Tohoku Alfresa Corporation
Representative: Shinya Uchida, President
Head offices (Sendai Headquarters): 4-8-5, Oroshimachi, Wakabayashi-ku, Sendai, Miyagi Prefecture
(Koriyama Headquarters): 1-46-1, Kikutamachi Oroshi, Koriyama, Fukushima Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

7 Alfresa Medical Service Corporation
Representative: Tamotsu Shioda, President
Head office: 2-3-14, Kudan-Minami, Chiyoda-ku, Tokyo
Business domain: SPD business (contract distribution service in hospitals) and wholesaling of medical materials

8 Alfresa Shinohara Chemicals Corporation
Representative: Yuichi Shinohara, President
Head office: 264-12, Otsuko, Kochi, Kochi Prefecture
Business domain: Wholesaling business of diagnostic reagents, research reagents, nursing care equipment, and analytical equipment for laboratories, etc.

9 A-L Plus Co., LTD.
Representative: Masahiko Hagino, President
Head office: 1-12-1, Uchikanda, Chiyoda-ku, Tokyo
Business domain: Pharmaceutical distribution and logistics (warehousing, transportation, delivery) and moving, office relocation, and storage

10 Specialty Medical Distribution Corporation
Representative: Yasuhide Sawado, President
Head office: 1, Kanda-Mitoshirocho, Chiyoda-ku, Tokyo
Business domain: Distribution of specialty pharmaceuticals, etc.

Self-Medication Products Wholesaling Business

11 Alfresa Healthcare Corporation
Representative: Makoto Nishida, President
Head office: 24-1, Nihonbashi-Hakozakicho, Chuo-ku, Tokyo
Business domain: Self-Medication Products Wholesaling Business

Manufacturing Business

12 Alfresa Pharma Corporation
Representative: Katsutoshi Araki, President & CEO
Head office: 2-2-9, Koku-machi, Chuo-ku, Osaka, Osaka Prefecture
Business domain: Manufacturing, import/export, and marketing of pharmaceuticals, diagnostic reagents, medical devices, and materials for pharmaceuticals, etc.

13 QINGDAO NESCO MEDICAL CO., LTD.
Representative: Yoshikazu Oe, Chairman
Head office: No. 11 Xinghai Rd., Chengyang, Qingdao, Shandong, China
Business domain: Manufacturing, export, and sale of surgical sutures

14 Alfresa Fine Chemical Corporation
Representative: Masaki Amano, President and CEO
Head office: 1-10-1, Mukaihamma, Akita, Akita Prefecture
Business domain: Manufacturing of active pharmaceutical ingredients

Dispensing Pharmacy and Related businesses

15 APOCREAT Corporation
Representative: Tomohide Tsuzuku, President
Head office: 4-5-2, Higashi-Ikebukuro, Toshima-ku, Tokyo
Business domain: Dispensing pharmacy business

Regenerative Medicine-Related Business

16 Cell Resources Corporation
Representative: Kotaro Arita, President
Head office: 1-4, Kanda-Ogawamachi, Chiyoda-ku, Tokyo
Business domain: Supply of cell materials, manufacturing of specified cell-processed products, manufacturing of regenerative medicine products, etc.

Information System Business for the Alfresa Group

17 Alfresa System Corporation
Representative: Naruhiko Sano, President
Head office: 1-1, Kandanishikicho, Chiyoda-ku, Tokyo
Business domain: Operation, maintenance, and development of information systems for the Alfresa Group

Corporate Overview

As of June 25, 2025

Corporate Name

Alfresa Holdings Corporation

Address

1-1-3, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

Established

September 29, 2003

Paid-in Capital

¥18,454 million

Representative

Ryuji Arakawa, Representative Director & President

Business

Managing subsidiaries that deal with wholesaling, manufacturing, marketing, and the import/export of pharmaceuticals, diagnostic reagents, medical devices/equipment, etc., and operating dispensing pharmacies and conducting related businesses



Alfresa Group Introduction Video

<https://youtu.be/8s-gK5BrQc0>



Corporate Website

<https://www.alfresa.com/eng/>